Navigation Links
Alcon Commences Phase 2 Clinical Trial of NovaBay's NVC-422 for Viral Conjunctivitis
Date:7/5/2009

f developing the first effective product to address viral conjunctivitis for which there are limited treatment options."

The Phase 2 multi-center, randomized, placebo-controlled trial is designed to determine the safety and efficacy of NVC-422 in people with viral conjunctivitis. The study calls for enrolling approximately 250 patients at more than 30 medical centers, mostly in the United States.

"This study is an important step forward with the clinical program for this potentially dual-acting therapy to address the multiple causes of conjunctivitis. Dual action against viral and bacterial conjunctivitis is important because when an infection is diagnosed it is difficult, time-consuming and expensive to determine the underlying cause of the infection and treat it properly," said Dr. Sabri Markabi, M.D., Alcon's senior vice president of research and development and chief medical officer.

About Conjunctivitis

Conjunctivitis, which can result from either viral or bacterial infection, is an inflammation of the thin, clear tissue that covers the white part of the eye and forms the inside lining of the eyelid. The viral disease is principally caused by adenoviruses, but also can be caused by other viruses, such as enterovirus. There is no specific treatment for adenoviral conjunctivitis, which can take up to three weeks or longer to clear on its own. Bacterial conjunctivitis is caused by a variety of bacteria and is largely treated with topically applied antibiotic eye drops. Regular innovation to develop newer antibiotics is required because over time antibiotics may encounter increasing bacterial resistance.

About Aganocide(R) Compounds

The Aganocide(R) compounds are novel, proprietary, synthetic N-chlorinated antimicrobial molecules specifically developed by NovaBay to mimic the body's natural defense against infection. The Aganocide(R) compounds maintain
'/>"/>

SOURCE NovaBay Pharmaceuticals, Inc.; Alcon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. ORBIS and Alcon Call Attention to the Aging Eye
2. Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
3. Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas
4. Novexels NXL104/ceftazidime Combination Commences Second Phase II Clinical Trial in Hospital Patients With Complicated Intra-Abdominal Infections (cIAIs)
5. VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology
6. Novexels NXL104/ceftazidime Combination Commences Phase II Clinical Trial in Hospital Patients With Complicated Urinary Tract Infections
7. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
8. Logical Therapeutics Inc. Commences Double-Blind, Randomized Study of Their Lead Program, LT-NS001
9. Cytopia Commences Second Phase II Study in Brain Cancer
10. Anesiva Commences Phase 2 Trial of Adlea(TM) in Arthroscopic Shoulder Surgery
11. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 5, 2015  Trovagene, Inc. (NASDAQ:  TROV), ... its financial results for the three months ended ... first quarter, we presented favorable clinical results at ... Conference, demonstrating our Precision Cancer Monitoring platform,s ability ... colorectal, and lung cancers," said Antonius Schuh, Ph.D., ...
(Date:5/5/2015)... -- IBM Watson Health (NYSE: IBM ) today announced ... leading cancer institutes to accelerate the ability of clinicians ... The institutes will apply Watson,s ... the ability to translate DNA insights, understand a person,s ... to personalize treatment options. The project is part of ...
(Date:5/5/2015)... WORTH, Texas , May 5, 2015 ... was valued at $94.9 million in 2014, and is ... a CAGR of 7.8% from 2014 to 2019. ... Glaucoma Surgery Device Market for an analysis of industry ... and figures. http://www.micromarketmonitor.com/market/north-america-glaucoma-surgery-devices-8830146604.html ...
Breaking Medicine Technology:Trovagene, Inc. Announces First Quarter 2015 Financial Results 2Trovagene, Inc. Announces First Quarter 2015 Financial Results 3Trovagene, Inc. Announces First Quarter 2015 Financial Results 4Trovagene, Inc. Announces First Quarter 2015 Financial Results 5Trovagene, Inc. Announces First Quarter 2015 Financial Results 6Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 2North America Ophthalmology Glaucoma Surgery Device Market is Expected to Reach $138.3 Million by 2019, at a CAGR of 7.8% From 2014 to 2019 3
... Inc. (Nasdaq: ANTH ), a biopharmaceutical company ... autoimmune disorders, today announced that it has appointed Dr. ... "Bogdan,s extensive global regulatory expertise and broad industry ... continue to navigate the evolving FDA regulatory landscape," said ...
... CLARK, N.J., March 5, 2012  Kerri Eckroat, RN, BSN, ... member of SurroundHealth , a free online community ... Eckroat said: "I believe that educating myself is crucial ... patients deserve the best. By learning from other healthcare ...
Cached Medicine Technology:Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board of Directors 2Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board of Directors 3SurroundHealth Online Community Reaches 1,000 Members 2SurroundHealth Online Community Reaches 1,000 Members 3
(Date:5/6/2015)... Viejo, CA (PRWEB) May 06, 2015 ... unique and fun self-animating generators for Final Cut ... to add stylistic titles to a Final Cut Pro ... environments, adding professional quality openers to any shot has ... any skill level in mind, saving users time while ...
(Date:5/6/2015)... 2015 Healthcare marketing agency Smith ... silver award in the 2015 Aster Awards for its ... Ellis Medicine’s maternity campaign, respectively. The Aster Awards recognize ... and marketing agencies. , The branding campaign for ... — other/misc. category and hospital 150-200 bed group. The ...
(Date:5/6/2015)... NY (PRWEB) May 06, 2015 The ... in New York City, announced today that it was ... Awards for a presentation video produced on behalf of ... in the category of motion graphics. , The competition ... (AMCP), received over 6000 entries from 22 countries. ...
(Date:5/6/2015)... 2015 The beverage industry has grocery ... Miracles organic tea and superfruit fusions stands out among ... sweetened with agave, these delicious juice blends are making ... healthier ways to hydrate. , In collaboration with National ... to raise a bottle of Lemongrass Tea and Ginseng, ...
(Date:5/5/2015)... 2015 With the FCPX LUT: Monochromatic pack ... easily add washed color grades to footage. A LUT is ... an image. The LUT changes every pixel's color to the ... 90 washed CUBE LUT files. , This plugin was inspired ... any footage a washed look. , CUBE LUT files ...
Breaking Medicine News(10 mins):Health News:Pixel Film Studios announces the release of Protrailer Cartoon Volume 2 for Final Cut Pro X. 2Health News:Smith & Jones Wins in 2015 Aster Awards for Healthcare Marketing 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2Health News:Say Cheers to National Beverage Day with Little Miracles 2Health News:Pixel Film Studios Announced the Release of FCPX LUT Monochromatic 2
... Yemen are declining because of an intensive awareness campaign ... for health workers, experts said recently, IRIN News reports. ... incidence in Yemen has decreased from 236 cases per ... people in 2005. During the same period, TB mortality ...
... demand from British Hindus and Sikhs to be allowed to ... major impetus with a charity //fighting for the cause being ... Ghai, president of the Anglo Asian Friendship Society, has been ... High Court judge, Justice Andrew Collins. ,The development ...
... starting their child's dental care, says German magazine "Baby and ... teeth. //Once a child has four or five teeth, switch ... their children about toothbrush use at age three. Most children ... the teeth, meaning parents have to help out with the ...
... major, Ranbaxy Laboratories Limited has achieved a significant ... ,The company’s New Drug Discovery Research (NDDR) team ... for respiratory inflammation. ,As per the ... companies in 2003, Ranbaxy will further profile this ...
... The Egg has over the years been a high source ... versatile food that can be eaten in several forms, it ... the world. With Easter just round the corner an animal ... on Wednesday urging people not to eat eggs. ...
... Lab Asia, a non--profit R&D organization functioning under the ... has taken up a project to map the health ... Indian state of Kerala. ,The two-year ... - Akshaya, is expected to utilize Information and Communication ...
Cached Medicine News:Health News:TB Cases, Deaths Decline in Yemen Because of Awareness Programs 2
... system device is comprised of the following ... creating each access port are also packaged ... insufflation and access needle, 14 gauge, 100 ... radially expandable sleeve, 100 mm length is ...
BLUNTPORT Plus Single Use Converterless 5 mm - 12 mm Trocar System for Open Laparoscopy....
... Auto Suture™ VERSAPORT™ PLUS V2 RT single-use obturator ... locking shield. , ,The Auto Suture™ VERSAPORT™ ... 5 -11, 5-12, 11 mm and 12 mm ... 5 mm and 5 mm short single-use obturators ...
... mm and VersaStep™ PLUS Reposable system components for creating ... The radial expandable sleeve is packaged sterile together with ... Insufflation and access needle is packaged non-sterile; ... dilators are packaged non-sterile; 5 mm, 7/8 mm, ...
Medicine Products: